Brokers Set Expectations for BEAM Q1 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Beam Therapeutics in a note issued to investors on Monday, February 3rd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.83) for the quarter. HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics' Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS and FY2029 earnings at ($1.44) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.01). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The firm had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.52 million. During the same quarter last year, the business posted ($1.22) earnings per share. The firm's revenue for the quarter was down 16.9% compared to the same quarter last year.

A number of other research analysts also recently commented on the company. Scotiabank started coverage on Beam Therapeutics in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $24.00 target price on the stock. Wedbush restated an "outperform" rating and issued a $57.00 price objective on shares of Beam Therapeutics in a report on Monday, January 13th. Royal Bank of Canada cut their price objective on shares of Beam Therapeutics from $27.00 to $24.00 and set a "sector perform" rating on the stock in a research report on Wednesday, November 6th. Leerink Partners raised shares of Beam Therapeutics from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $27.00 to $39.00 in a research report on Wednesday, November 6th. Finally, Cantor Fitzgerald upgraded shares of Beam Therapeutics from a "neutral" rating to an "overweight" rating in a report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Beam Therapeutics has an average rating of "Buy" and a consensus target price of $47.67.

Beam Therapeutics Stock Performance

Shares of BEAM stock traded down $0.17 during trading on Tuesday, hitting $27.65. 1,496,937 shares of the company were exchanged, compared to its average volume of 1,145,218. The firm has a market capitalization of $2.29 billion, a price-to-earnings ratio of -15.71 and a beta of 1.92. The business's 50-day simple moving average is $26.49 and its 200 day simple moving average is $25.77. Beam Therapeutics has a twelve month low of $20.84 and a twelve month high of $49.50.

Insider Activity

In other news, insider Christine Bellon sold 1,241 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the sale, the insider now owns 102,968 shares in the company, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John M. Evans sold 30,000 shares of the business's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $26.75, for a total transaction of $802,500.00. Following the transaction, the chief executive officer now directly owns 908,659 shares in the company, valued at $24,306,628.25. This trade represents a 3.20 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Beam Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its holdings in Beam Therapeutics by 6.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 629,492 shares of the company's stock valued at $15,423,000 after acquiring an additional 36,226 shares in the last quarter. Bellevue Group AG increased its position in shares of Beam Therapeutics by 7.1% during the third quarter. Bellevue Group AG now owns 1,518,121 shares of the company's stock valued at $37,194,000 after purchasing an additional 100,000 shares during the period. Geode Capital Management LLC increased its position in shares of Beam Therapeutics by 4.5% during the third quarter. Geode Capital Management LLC now owns 1,807,683 shares of the company's stock valued at $44,297,000 after purchasing an additional 78,102 shares during the period. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Beam Therapeutics by 59.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,552,829 shares of the company's stock valued at $87,044,000 after purchasing an additional 1,328,414 shares in the last quarter. Finally, Algert Global LLC lifted its position in Beam Therapeutics by 282.0% in the third quarter. Algert Global LLC now owns 43,523 shares of the company's stock worth $1,066,000 after purchasing an additional 32,130 shares during the period. Institutional investors own 99.68% of the company's stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.